The present disclosure provides a method of treating peri-orbital fullness in a subject upon determining if the subject exhibits pseudoherniation of one or more upper eyelid fat pads and/or one or more lower eyelid fat pads, determining if the subject exhibits one or more conditions selected from the group consisting of: edema of the fat pad, edema along the soft tissue of the upper and/or lower eyelids, malar mounds due to edema, malar edema, and mild festoons aggravated by edema, and scoring the peri-orbital fullness from both determinations.

Methods and systems for scoring hyaluronan-stained tissue samples by assessing the area of tumor-associated extracellular matrix (ECM) with hyaluronan staining compared to the entire surface area of the relevant portion of the sample. The methods and systems of the present disclosure may be used to, for example, to select patients for receipt of specific treatments.

This disclosure relates to compositions capable of use in the treatment of spinal cord injuries and related disorders of the central nervous system (CNS), and in particular, compositions including proteoglycan degrading molecules and compositions capable of blocking and/or over coming the activity of neuronal growth inhibitory molecules, as well as fusion proteins which includes a proteoglycan degrading domain and a domain capable of blocking and or over coming the activity of neuronal growth inhibitory molecules.

The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (CNS) injury or disease.